This case report describes the treatment of a 74-year-old female patient carrying an EML4-ALK fusion gene mutation in SCLC who developed recurrence of hilar lymph node metastasis three years after surgical resection and was treated with ensartinib targeting the EML4-ALK fusion gene mutation. Here, ALK is linked to small cell lung carcinoma.